Immunology : what's new in 2023
Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting various organs and characterized by profound immune disturbances. Monoclonal antibodies such as anifrolumab, targeting type I interferon, and belimumab, targeting a cytokine that activates B-cells and plasmocytes, have shown efficacy in SLE. Voclosporine, a novel calcineurin inhibitor, improves renal outcomes when combined with standard immunosuppression in lupus nephritis. Other approaches like obinutuzumab and CAR-T cells offer hope for refractory patients. These advances diversify SLE management, though their long-term efficacy remains to be established. It is crucial to emphasize basic measures in patients with SLE, including smoking cessation, sun protection, and early use of hydroxychloroquine.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Revue medicale suisse - 20(2024), 856-7 vom: 17. Jan., Seite 47-50 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Immunologie: ce qui a changé en 2023 |
|---|
| Beteiligte Personen: |
Ringwald, Maxime [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 18.01.2024 Date Revised 18.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.53738/REVMED.2024.20.856-7.47 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367216590 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367216590 | ||
| 003 | DE-627 | ||
| 005 | 20240118232148.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240117s2024 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.53738/REVMED.2024.20.856-7.47 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1263.xml |
| 035 | |a (DE-627)NLM367216590 | ||
| 035 | |a (NLM)38231099 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Ringwald, Maxime |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunology |b what's new in 2023 |
| 246 | 3 | 3 | |a Immunologie: ce qui a changé en 2023 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.01.2024 | ||
| 500 | |a Date Revised 18.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting various organs and characterized by profound immune disturbances. Monoclonal antibodies such as anifrolumab, targeting type I interferon, and belimumab, targeting a cytokine that activates B-cells and plasmocytes, have shown efficacy in SLE. Voclosporine, a novel calcineurin inhibitor, improves renal outcomes when combined with standard immunosuppression in lupus nephritis. Other approaches like obinutuzumab and CAR-T cells offer hope for refractory patients. These advances diversify SLE management, though their long-term efficacy remains to be established. It is crucial to emphasize basic measures in patients with SLE, including smoking cessation, sun protection, and early use of hydroxychloroquine | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 700 | 1 | |a Ribi, Camillo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue medicale suisse |d 2005 |g 20(2024), 856-7 vom: 17. Jan., Seite 47-50 |w (DE-627)NLM154244252 |x 1660-9379 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2024 |g number:856-7 |g day:17 |g month:01 |g pages:47-50 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.53738/REVMED.2024.20.856-7.47 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2024 |e 856-7 |b 17 |c 01 |h 47-50 | ||